Novel Azaquinolones as PARP1 Inhibitors for Treating Cancer.
Basic Information
ID: ALA4814061
Journal: ACS Med Chem Lett
Title: Novel Azaquinolones as PARP1 Inhibitors for Treating Cancer.
Authors: Sabnis RW.
Abstract: Store-operated calcium entry (SOCE) is a pivotal mechanism in calcium homeostasis, and, despite still being under investigation, its dysregulation is known to be associated with severe human disorders. SOCE modulators are therefore needed both as chemical probes and as therapeutic agents. While many small molecules have been described so far, their poor properties in terms of drug-likeness have limited their translation into the clinical practice. In this work, we describe the bioisosteric replacement of the ester moiety in pyrazole derivatives with a 1,2,4-oxadiazole ring as a means to afford a class of modulators with high metabolic stability. Moreover, among our derivatives, a compound able to increase the calcium entry was identified, further enriching the library of available SOCE activators.
CiteXplore: 33859786
DOI: 10.1021/acsmedchemlett.1c00122
Patent ID: ┄